Wells Fargo’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $142 | Sell |
250
-480
| -66% | -$328 | ﹤0.01% | 6476 |
|
|
2025
Q4 | $467 | Hold |
730
| – | – | ﹤0.01% | 6340 |
|
|
2025
Q3 | $682 | Hold |
730
| – | – | ﹤0.01% | 6281 |
|
|
2025
Q2 | $934 | Buy |
730
+480
| +192% | +$482 | ﹤0.01% | 6313 |
|
|
2025
Q1 | $250 | Hold |
250
| – | – | ﹤0.01% | 6315 |
|
|
2024
Q4 | $228 | Hold |
250
| – | – | ﹤0.01% | 6351 |
|
|
2024
Q3 | $375 | Sell |
250
-203
| -45% | -$223 | ﹤0.01% | 6186 |
|
|
2024
Q2 | $319 | Sell |
453
-343
| -43% | -$297 | ﹤0.01% | 6177 |
|
|
2024
Q1 | $757 | Buy |
796
+255
| +47% | +$248 | ﹤0.01% | 6214 |
|
|
2023
Q4 | $601 | Buy |
541
+16
| +3% | +$24 | ﹤0.01% | 6341 |
|
|
2023
Q3 | $987 | Sell |
525
-13
| -2% | -$37 | ﹤0.01% | 6206 |
|
|
2023
Q2 | $1.93K | Buy |
538
+13
| +2% | +$41 | ﹤0.01% | 6210 |
|
|
2023
Q1 | $1.77K | Buy |
525
+5
| +1% | +$15 | ﹤0.01% | 6250 |
|
|
2022
Q4 | $807 | Sell |
520
-3,993
| -88% | -$5.92K | ﹤0.01% | 6254 |
|
|
2022
Q3 | $6K | Sell |
4,513
-38
| -0.8% | -$74 | ﹤0.01% | 5846 |
|
|
2022
Q2 | $10K | Sell |
4,551
-13,690
| -75% | -$31.4K | ﹤0.01% | 5743 |
|
|
2022
Q1 | $59K | Sell |
18,241
-14,779
| -45% | -$52.9K | ﹤0.01% | 5570 |
|
|
2021
Q4 | $139K | Buy |
33,020
+23,666
| +253% | +$133K | ﹤0.01% | 5468 |
|
|
2021
Q3 | $76K | Buy |
9,354
+62
| +0.7% | +$504 | ﹤0.01% | 5480 |
|
|
2021
Q2 | $71K | Sell |
9,292
-94,831
| -91% | -$799K | ﹤0.01% | 5425 |
|
|
2021
Q1 | $903K | Sell |
104,123
-636
| -0.6% | -$6.06K | ﹤0.01% | 4313 |
|
|
2020
Q4 | $835K | Buy |
104,759
+1,580
| +2% | +$13.2K | ﹤0.01% | 4165 |
|
|
2020
Q3 | $823K | Buy |
103,179
+9,557
| +10% | +$86.2K | ﹤0.01% | 4002 |
|
|
2020
Q2 | $926K | Buy |
93,622
+59,940
| +178% | +$550K | ﹤0.01% | 3869 |
|
|
2020
Q1 | $260K | Buy |
33,682
+10,172
| +43% | +$51.3K | ﹤0.01% | 4502 |
|
|
2019
Q4 | $91K | Sell |
23,510
-2,583
| -10% | -$11.3K | ﹤0.01% | 5339 |
|
|
2019
Q3 | $132K | Buy |
26,093
+880
| +3% | +$5.12K | ﹤0.01% | 5188 |
|
|
2019
Q2 | $167K | Sell |
25,213
-34,883
| -58% | -$240K | ﹤0.01% | 5072 |
|
|
2019
Q1 | $455K | Buy |
60,096
+4,154
| +7% | +$32.3K | ﹤0.01% | 4395 |
|
|
2018
Q4 | $452K | Buy |
55,942
+15,409
| +38% | +$153K | ﹤0.01% | 4395 |
|
|
2018
Q3 | $522K | Sell |
40,533
-17,364
| -30% | -$218K | ﹤0.01% | 4403 |
|
|
2018
Q2 | $660K | Buy |
57,897
+37,048
| +178% | +$351K | ﹤0.01% | 4261 |
|
|
2018
Q1 | $147K | Sell |
20,849
-80
| -0.4% | -$605 | ﹤0.01% | 5137 |
|
|
2017
Q4 | $136K | Buy |
20,929
+13,515
| +182% | +$86K | ﹤0.01% | 5169 |
|
|
2017
Q3 | $46K | Buy |
+7,414
| New | +$37.8K | ﹤0.01% | 5495 |
|
|
2017
Q1 | – | Sell |
-1,500
| Closed | -$8K | – | 6323 |
|
|
2016
Q4 | $8K | Buy |
+1,500
| New | +$8.21K | ﹤0.01% | 5855 |
|
|
2016
Q2 | – | Sell |
-1,263
| Closed | -$5K | – | 6122 |
|
|
2016
Q1 | $5K | Sell |
1,263
-9,054
| -88% | -$39.3K | ﹤0.01% | 5859 |
|
|
2015
Q4 | $57K | Buy |
+10,317
| New | +$70.2K | ﹤0.01% | 5232 |
|
|
2015
Q3 | – | Sell |
-120
| Closed | -$1K | – | 6229 |
|
|
2015
Q2 | $1K | Sell |
120
-336
| -74% | -$2.29K | ﹤0.01% | 6223 |
|
|
2015
Q1 | $6K | Buy |
+456
| New | +$4.69K | ﹤0.01% | 5772 |
|
Other funds holding CTSO
AC
VCM
SC
CM
SIG
VFT
Wells Fargo's CTSO Position: Q1 2026 in Review
Wells Fargo reduced its Cytosorbents Corp (CTSO) stake by 66% in Q1 2026, selling an estimated $328 and leaving 250 shares worth $142. The position accounts for ﹤0.01% of the portfolio, ranked #6476.
Wells Fargo first reported a position in CTSO in Q1 2015 and has held it in 40 quarters since. The position peaked at $926K in Q2 2020. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.
- Wells Fargo held 250 shares of Cytosorbents Corp worth $142 as of Q1 2026.
- Wells Fargo sold 480 Cytosorbents Corp shares in Q1 2026, an estimated $328.
- Cytosorbents Corp made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6476 holding.
- Wells Fargo first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 40 quarters since.
- Wells Fargo's Cytosorbents Corp position peaked at $926K in Q2 2020.
- 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.